Greiner Bio Financial Performance

Greiner Bio-One (GBO) had a financial year that was as successful as it was eventful. New product solutions were launched onto the market, such as the VACUETTE^® GLUCOMEDICS tubes for effective glycolysis inhibition or the new VACUETTE^® TUBE TOUCH safety tube holders for avoiding needle-stick injuries. The integration of the new sites in China and India was also developed and the company‘s market share expanded further.

Financial year 2013

The financial year 2013 was marked by persistently high raw material prices. On average, the price of polystyrene was 10 per cent higher than last year alone. Sales rose in 2013 despite noticeably negative currency effects by three per cent from Euro 364 million to Euro 373 million. Cash flow also increased by Euro 10 million from Euro 32 million in 2012 to Euro 42 million. GBO invested around Euro 15 million. In December 2013, the company employed 1,728 people at 23 sites in Europe, North and South America and Asia.

Sales and cash flow:

2010 to 2013 in Euro Million

The importance of the diagnostics market has grown increasingly in recent years. Greiner Bio-One‘s subsidiary Lambda has been successful in this field for many years now. In recognition of this high future growth potential, a separate business unit called Greiner Bio-One Diagnostics has been created. Greiner Bio-One Diagnostics is based in Rainbach im Mühlkreis (Upper Austria). With this new division, Greiner Bio-One services customers from the Preanalytics sector (hospitals) and customers of Greiner Bio-One BioScience (the pharmaceutical industry and large diagnostic laboratories). In future, the company will focus increasingly on the development of quick tests.

The financial year 2014 has started well for Greiner Bio-One. New product solutions on the market, such as the VACUETTE^® CCM urine tubes or the Cryo.s Biobank tubes, are expanding the company‘s existing product portfolio.

Know more about Greiner Bio One: https://www.gbo.com/en_INT/